News Release 2019
-
- November 19, 2019
- NHI Drug Price Listing and Release of Oral Quinolone Antibacterial Agent "Lasvic®Tablets 75mg"
-
- November 7, 2019
- Summary of Consolidated Financial Results (For the Second Quarter Ended September 30, 2019) [Japanese Standard]
-
- November 7, 2019
- Second Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2020 - Supplementary Information
-
- November 7, 2019
- The Revision of Consolidated Financial Forecasts for Fiscal Year Ending March 31, 2020
-
- November 7, 2019
- Absorption-type Merger between the Consolidated Subsidiaries
-
- November 7, 2019
- KYORIN and JEIL Signed License Agreement for Vibegron in Korea
-
- November 5, 2019
- Revision of Consolidated Financial Forecasts
-
- October 29, 2019
- Release of Microchannel-based Genetic Measurement Device GeneSoC®
-
- October 28, 2019
- Resumption of Supply of Desalex® Tablets 5mg Long-Acting Selective H1 Receptor Antagonist for Allergic Diseases Treatment
-
- September 20, 2019
- Kyorin Pharmaceutical Receives Marketing Approval for Oral Quinolone Antibacterial Agent "Lasvic®Tablets 75mg"
-
- August 23, 2019
- Release of Mometasone Nasal 50μg「KYORIN」56sprays, 112sprays
-
- July 31, 2019
- Summary of Consolidated Financial Results(July 31,2019)
-
- July 31, 2019
- First Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2020
-
- May 14, 2019
- Financial Results for Fiscal 2018
-
- May 13, 2019
- Summary of Consolidated Financial Results (For the fiscal year ended March 31, 2019) [Japanese Standard]
-
- May 13, 2019
- Consolidated Financial Results for the Fiscal Year Ending March 31, 2019
-
- May 13, 2019
- Kyorin Signed Memorandum of Understanding on Marketing Collaboration with respect to Chronic Cough Treatment
-
- April 2, 2019
- Release of Alcohol-Free Hand Sanitizer Noahtect® Pro
-
- March 27, 2019
- Conclusion of Agreement on OTC Drug Marketing Rights with DER UAW PHARMACEUTICAL CO., LTD.
-
- March 27, 2019
- Conclusion of Agreement with Monospharm Trade Co., Ltd. Concerning Marketing Rights for Generic Medicines
-
- February 5, 2019
- Summary of Consolidated Financial Results (For the Third Quarter Ended Dec 31, 2018) [Japanese Standard]
-
- February 5, 2019
- Third Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2019 - Supplementary Information
-
- February 5, 2019
- The Revision of Consolidated Financial Forecasts for Fiscal Year Ending March 31, 2019
-
- January 7, 2019
- Impact on Kyorin's Financial Performance of MSD's Decision to Voluntarily Recall Desalex® Tablets 5mg Long-Acting Selective H1 Receptor Antagonist for Allergic Diseases Treatment
